848 related articles for article (PubMed ID: 19298320)
1. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
2. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
[TBL] [Abstract][Full Text] [Related]
3. Alterations in striatal neuropeptide Y system activity of rats with haloperidol-induced behavioral supersensitivity.
Obuchowicz E; Krysiak R; Wieronska JM; Smialowska M; Herman ZS
Neuropeptides; 2005 Oct; 39(5):515-23. PubMed ID: 16154634
[TBL] [Abstract][Full Text] [Related]
4. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
Fukushiro DF; Carvalho Rde C; Ricardo VP; Alvarez Jdo N; Ribeiro LT; Frussa-Filho R
Brain Res Bull; 2008 Sep; 77(2-3):124-8. PubMed ID: 18721669
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment.
Zhang Y; Xu H; He J; Yan B; Jiang W; Li X; Li XM
Neurosci Lett; 2007 Jun; 420(1):66-71. PubMed ID: 17466452
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
Schröder U; Schröder H; Augustin W; Sabel BA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
[TBL] [Abstract][Full Text] [Related]
9. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
De Veaugh-Geiss J; Devanand DP; Carey RJ
Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
[TBL] [Abstract][Full Text] [Related]
10. D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period.
Joyce JN
Synapse; 2001 May; 40(2):137-44. PubMed ID: 11252025
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
12. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice.
Fukushiro DF; Alvarez Jdo N; Tatsu JA; de Castro JP; Chinen CC; Frussa-Filho R
Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):867-72. PubMed ID: 17368685
[TBL] [Abstract][Full Text] [Related]
13. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
Bartoszyk GD; Harting J; Minck KO
J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
Xu R; Hranilovic D; Fetsko LA; Bucan M; Wang Y
Mol Psychiatry; 2002; 7(10):1075-82. PubMed ID: 12476322
[TBL] [Abstract][Full Text] [Related]
15. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Janssen PA; Awouters FH
Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
[TBL] [Abstract][Full Text] [Related]
16. The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?
Logue SF; Grauer SM; Paulsen J; Graf R; Taylor N; Sung MA; Zhang L; Hughes Z; Pulito VL; Liu F; Rosenzweig-Lipson S; Brandon NJ; Marquis KL; Bates B; Pausch M
Mol Cell Neurosci; 2009 Dec; 42(4):438-47. PubMed ID: 19796684
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
Staunton DA; Magistretti PJ; Shoemaker WJ; Deyo SN; Bloom FE
Brain Res; 1982 Jan; 232(2):401-12. PubMed ID: 6322915
[TBL] [Abstract][Full Text] [Related]
18. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
Surmann A; Havemann-Reinecke U
J Neural Transm Suppl; 1995; 45():143-55. PubMed ID: 8748620
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain.
O'Dell SJ; La Hoste GJ; Widmark CB; Shapiro RM; Potkin SG; Marshall JF
Synapse; 1990; 6(2):146-53. PubMed ID: 2237777
[TBL] [Abstract][Full Text] [Related]
20. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment.
Vonvoigtlander PF; Losey EG; Triezenberg HJ
J Pharmacol Exp Ther; 1975 Apr; 193(1):88-94. PubMed ID: 166158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
